Jazz Pharmaceuticals (NASDAQ:JAZZ) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note released on Friday, Benzinga reports. They currently have a $200.00 price objective on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other research reports. Stifel Nicolaus increased their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a buy rating in a research note on Friday, March 15th. Truist Financial reissued a buy rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Barclays decreased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating for the company in a report on Friday. StockNews.com downgraded shares of Jazz Pharmaceuticals from a strong-buy rating to a buy rating in a report on Thursday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an overweight rating in a research report on Friday, March 22nd. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $192.75.

Jazz Pharmaceuticals Stock Up 0.7 %

Jazz Pharmaceuticals stock traded up $0.72 during mid-day trading on Friday, hitting $110.01. The company’s stock had a trading volume of 693,769 shares, compared to its average volume of 597,957. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.85. Jazz Pharmaceuticals has a 52-week low of $103.01 and a 52-week high of $146.70. The firm’s 50 day moving average is $116.44 and its 200 day moving average is $121.10. The company has a market cap of $6.94 billion, a PE ratio of 22.68, a price-to-earnings-growth ratio of 1.51 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. On average, analysts anticipate that Jazz Pharmaceuticals will post 16.24 earnings per share for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Philip L. Johnson acquired 12,000 shares of the stock in a transaction dated Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in JAZZ. SG Americas Securities LLC acquired a new position in Jazz Pharmaceuticals in the third quarter worth $611,000. Asset Management One Co. Ltd. grew its stake in shares of Jazz Pharmaceuticals by 12.0% during the third quarter. Asset Management One Co. Ltd. now owns 28,124 shares of the specialty pharmaceutical company’s stock valued at $3,640,000 after purchasing an additional 3,004 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Jazz Pharmaceuticals by 10.6% in the third quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company’s stock valued at $1,304,000 after purchasing an additional 962 shares in the last quarter. Pinnacle Associates Ltd. raised its position in Jazz Pharmaceuticals by 2.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 10,587 shares of the specialty pharmaceutical company’s stock worth $1,370,000 after purchasing an additional 238 shares during the last quarter. Finally, Forsta AP Fonden raised its position in shares of Jazz Pharmaceuticals by 15.2% during the third quarter. Forsta AP Fonden now owns 22,000 shares of the specialty pharmaceutical company’s stock worth $2,848,000 after acquiring an additional 2,900 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.